Inmaculada C. Penades
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Sarilumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Dose-Finding and 1-Year Analysis of a Phase 2b, Open-Label, Multicenter Study.
Journal: Arthritis care & research
Published: January 22, 2025
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 08, 2024
Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: January 19, 2023
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring.
Journal: Arthritis care & research
Published: September 30, 2021
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Journal: Rheumatology (Oxford, England)
Published: July 28, 2020
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: May 15, 2020
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
Journal: Pediatric rheumatology online journal
Published: June 07, 2019
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.
Journal: Annals of the rheumatic diseases
Published: June 28, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026